Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 44 | 2024 | 865 | 13.760 |
Why?
|
| Pre-Exposure Prophylaxis | 17 | 2024 | 157 | 8.430 |
Why?
|
| Anti-HIV Agents | 17 | 2024 | 164 | 6.930 |
Why?
|
| Emergency Service, Hospital | 10 | 2024 | 535 | 2.790 |
Why?
|
| Electronic Health Records | 7 | 2024 | 360 | 2.610 |
Why?
|
| Sexual and Gender Minorities | 7 | 2024 | 222 | 2.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2024 | 538 | 1.870 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 308 | 1.570 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2024 | 267 | 1.500 |
Why?
|
| Chicago | 16 | 2024 | 1452 | 1.460 |
Why?
|
| Betacoronavirus | 4 | 2020 | 264 | 1.390 |
Why?
|
| Health Personnel | 3 | 2024 | 216 | 1.350 |
Why?
|
| Medical Informatics | 2 | 2021 | 50 | 1.330 |
Why?
|
| Clostridium Infections | 2 | 2023 | 125 | 1.320 |
Why?
|
| Homosexuality, Male | 8 | 2023 | 313 | 1.290 |
Why?
|
| Telemedicine | 2 | 2022 | 200 | 1.280 |
Why?
|
| Ambulatory Care Facilities | 5 | 2023 | 112 | 1.270 |
Why?
|
| Humans | 77 | 2024 | 91074 | 1.260 |
Why?
|
| Disease Transmission, Infectious | 2 | 2020 | 58 | 1.250 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 322 | 1.210 |
Why?
|
| Adult | 37 | 2024 | 27147 | 1.190 |
Why?
|
| Female | 45 | 2024 | 47186 | 1.120 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2023 | 99 | 1.090 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 55 | 0.990 |
Why?
|
| Epidemiological Monitoring | 2 | 2016 | 38 | 0.970 |
Why?
|
| Pandemics | 11 | 2022 | 792 | 0.960 |
Why?
|
| Middle Aged | 31 | 2024 | 26555 | 0.960 |
Why?
|
| AIDS Serodiagnosis | 3 | 2022 | 26 | 0.910 |
Why?
|
| Contact Tracing | 2 | 2021 | 29 | 0.880 |
Why?
|
| Algorithms | 5 | 2024 | 1933 | 0.880 |
Why?
|
| Natural Language Processing | 2 | 2021 | 41 | 0.870 |
Why?
|
| Sexual Partners | 3 | 2024 | 102 | 0.860 |
Why?
|
| Male | 37 | 2024 | 43249 | 0.860 |
Why?
|
| Risk Assessment | 3 | 2020 | 2345 | 0.850 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 81 | 0.820 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 34 | 0.820 |
Why?
|
| Influenza, Human | 2 | 2016 | 342 | 0.820 |
Why?
|
| Antimicrobial Stewardship | 2 | 2021 | 23 | 0.780 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 389 | 0.770 |
Why?
|
| Hepatitis C | 1 | 2023 | 176 | 0.740 |
Why?
|
| United States | 13 | 2024 | 7188 | 0.720 |
Why?
|
| Hospitalization | 5 | 2022 | 903 | 0.700 |
Why?
|
| Viral Load | 4 | 2024 | 145 | 0.700 |
Why?
|
| Virus Shedding | 1 | 2020 | 27 | 0.700 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 9 | 0.690 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2021 | 103 | 0.690 |
Why?
|
| Retrospective Studies | 20 | 2024 | 9400 | 0.690 |
Why?
|
| Ambulatory Care | 2 | 2023 | 189 | 0.680 |
Why?
|
| Continuity of Patient Care | 4 | 2024 | 170 | 0.670 |
Why?
|
| Respiratory System | 1 | 2020 | 118 | 0.660 |
Why?
|
| HIV-1 | 1 | 2020 | 163 | 0.660 |
Why?
|
| Qualitative Research | 4 | 2024 | 318 | 0.650 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.650 |
Why?
|
| Patient Compliance | 1 | 2021 | 231 | 0.650 |
Why?
|
| Infection Control | 1 | 2020 | 124 | 0.640 |
Why?
|
| RNA, Viral | 1 | 2020 | 320 | 0.640 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 13 | 0.620 |
Why?
|
| Heterosexuality | 1 | 2018 | 19 | 0.610 |
Why?
|
| Travel | 1 | 2018 | 72 | 0.590 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 77 | 0.590 |
Why?
|
| Referral and Consultation | 1 | 2020 | 352 | 0.570 |
Why?
|
| Cross Infection | 2 | 2016 | 151 | 0.570 |
Why?
|
| Antifungal Agents | 3 | 2017 | 123 | 0.570 |
Why?
|
| Coinfection | 4 | 2021 | 63 | 0.560 |
Why?
|
| Anti-Bacterial Agents | 6 | 2023 | 803 | 0.560 |
Why?
|
| Itraconazole | 1 | 2016 | 11 | 0.540 |
Why?
|
| Residence Characteristics | 1 | 2018 | 204 | 0.530 |
Why?
|
| Violence | 1 | 2018 | 155 | 0.530 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 39 | 0.530 |
Why?
|
| Sorbitol | 1 | 2016 | 9 | 0.520 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 8 | 0.520 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 65 | 0.520 |
Why?
|
| Population Surveillance | 1 | 2016 | 209 | 0.500 |
Why?
|
| Automation | 1 | 2016 | 112 | 0.500 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 156 | 0.480 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 35 | 0.470 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 23 | 0.460 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 151 | 0.460 |
Why?
|
| Machine Learning | 3 | 2022 | 278 | 0.450 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 52 | 0.450 |
Why?
|
| Hospitals | 1 | 2016 | 309 | 0.450 |
Why?
|
| Focus Groups | 2 | 2024 | 182 | 0.440 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 151 | 0.440 |
Why?
|
| Young Adult | 10 | 2024 | 6502 | 0.410 |
Why?
|
| Candida | 3 | 2017 | 18 | 0.410 |
Why?
|
| Logistic Models | 3 | 2022 | 1216 | 0.410 |
Why?
|
| Candidiasis | 3 | 2017 | 37 | 0.400 |
Why?
|
| Mass Screening | 5 | 2024 | 646 | 0.390 |
Why?
|
| Sepsis | 1 | 2016 | 330 | 0.390 |
Why?
|
| Risk Factors | 6 | 2023 | 5608 | 0.380 |
Why?
|
| Comorbidity | 4 | 2023 | 963 | 0.370 |
Why?
|
| Time Factors | 5 | 2022 | 5378 | 0.370 |
Why?
|
| Electronics | 2 | 2021 | 17 | 0.370 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 272 | 0.360 |
Why?
|
| Cities | 2 | 2021 | 53 | 0.350 |
Why?
|
| Soft Tissue Infections | 2 | 2021 | 26 | 0.340 |
Why?
|
| Vaccination | 2 | 2022 | 281 | 0.340 |
Why?
|
| Syphilis | 2 | 2021 | 33 | 0.330 |
Why?
|
| Inpatients | 3 | 2021 | 320 | 0.330 |
Why?
|
| Adolescent | 9 | 2024 | 9411 | 0.300 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2021 | 150 | 0.300 |
Why?
|
| Models, Theoretical | 2 | 2021 | 491 | 0.290 |
Why?
|
| Aged | 14 | 2021 | 19574 | 0.290 |
Why?
|
| Urban Population | 2 | 2018 | 227 | 0.280 |
Why?
|
| Pilot Projects | 3 | 2024 | 887 | 0.270 |
Why?
|
| Survival Analysis | 2 | 2022 | 1500 | 0.250 |
Why?
|
| Medicare | 2 | 2020 | 432 | 0.250 |
Why?
|
| Community-Acquired Infections | 2 | 2021 | 64 | 0.230 |
Why?
|
| Patient Portals | 1 | 2024 | 18 | 0.230 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2020 | 68 | 0.210 |
Why?
|
| Program Evaluation | 1 | 2024 | 313 | 0.210 |
Why?
|
| Age Factors | 2 | 2018 | 1876 | 0.200 |
Why?
|
| Social Support | 1 | 2024 | 220 | 0.200 |
Why?
|
| Social Media | 1 | 2024 | 100 | 0.200 |
Why?
|
| Safe Sex | 2 | 2020 | 24 | 0.200 |
Why?
|
| Prospective Studies | 2 | 2021 | 4367 | 0.200 |
Why?
|
| Anxiety | 1 | 2024 | 316 | 0.190 |
Why?
|
| Feasibility Studies | 1 | 2024 | 791 | 0.190 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2021 | 25 | 0.190 |
Why?
|
| HIV | 1 | 2021 | 49 | 0.180 |
Why?
|
| Hospitals, Urban | 1 | 2021 | 61 | 0.180 |
Why?
|
| Minority Groups | 1 | 2022 | 148 | 0.180 |
Why?
|
| Lost to Follow-Up | 1 | 2021 | 15 | 0.180 |
Why?
|
| Demography | 1 | 2021 | 184 | 0.180 |
Why?
|
| Needle Sharing | 1 | 2020 | 15 | 0.180 |
Why?
|
| Risk Management | 1 | 2020 | 43 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 10 | 0.180 |
Why?
|
| Azithromycin | 1 | 2020 | 13 | 0.180 |
Why?
|
| Drug Resistance, Multiple, Fungal | 2 | 2017 | 3 | 0.170 |
Why?
|
| Postal Service | 1 | 2020 | 16 | 0.170 |
Why?
|
| Cephalosporins | 1 | 2020 | 24 | 0.170 |
Why?
|
| Serologic Tests | 1 | 2020 | 43 | 0.170 |
Why?
|
| Social Networking | 1 | 2021 | 77 | 0.170 |
Why?
|
| Depression | 1 | 2024 | 517 | 0.170 |
Why?
|
| Critical Illness | 1 | 2023 | 317 | 0.170 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 73 | 0.170 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1753 | 0.170 |
Why?
|
| Bias | 1 | 2020 | 136 | 0.160 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 439 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 210 | 0.160 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2019 | 8 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 863 | 0.160 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 652 | 0.160 |
Why?
|
| Condoms | 1 | 2019 | 39 | 0.160 |
Why?
|
| Geographic Information Systems | 1 | 2018 | 24 | 0.150 |
Why?
|
| Geographic Mapping | 1 | 2018 | 12 | 0.150 |
Why?
|
| Illinois | 1 | 2020 | 499 | 0.150 |
Why?
|
| Crime | 1 | 2018 | 37 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2018 | 170 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 888 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2024 | 800 | 0.150 |
Why?
|
| Risk-Taking | 1 | 2019 | 157 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2020 | 433 | 0.140 |
Why?
|
| Perception | 1 | 2018 | 181 | 0.140 |
Why?
|
| Interviews as Topic | 1 | 2018 | 348 | 0.140 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 18 | 0.130 |
Why?
|
| Organ Transplantation | 1 | 2020 | 286 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2033 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2016 | 67 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2016 | 26 | 0.130 |
Why?
|
| Food Service, Hospital | 1 | 2016 | 4 | 0.130 |
Why?
|
| Penicillins | 1 | 2016 | 23 | 0.130 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 37 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1877 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2682 | 0.130 |
Why?
|
| Medicaid | 1 | 2018 | 244 | 0.120 |
Why?
|
| Seasons | 1 | 2016 | 242 | 0.120 |
Why?
|
| Sexual Behavior | 1 | 2018 | 317 | 0.120 |
Why?
|
| Nasopharynx | 1 | 2015 | 50 | 0.120 |
Why?
|
| Pneumonia | 1 | 2016 | 185 | 0.120 |
Why?
|
| Bacteriuria | 1 | 2014 | 10 | 0.120 |
Why?
|
| Viruses | 1 | 2015 | 78 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2016 | 238 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2014 | 76 | 0.110 |
Why?
|
| Infant | 2 | 2019 | 3204 | 0.110 |
Why?
|
| Obesity | 1 | 2020 | 989 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2020 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2019 | 3790 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 925 | 0.100 |
Why?
|
| Child | 3 | 2020 | 7273 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6847 | 0.100 |
Why?
|
| Trust | 2 | 2023 | 97 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 854 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 852 | 0.090 |
Why?
|
| Social Stigma | 2 | 2022 | 72 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2014 | 407 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1892 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 171 | 0.090 |
Why?
|
| Bacteria | 1 | 2014 | 497 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 2 | 2019 | 55 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 2 | 1999 | 175 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2020 | 8436 | 0.070 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2017 | 13 | 0.070 |
Why?
|
| Prevalence | 2 | 2022 | 1265 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2016 | 299 | 0.060 |
Why?
|
| Global Health | 2 | 2017 | 194 | 0.060 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 23 | 0.060 |
Why?
|
| France | 1 | 2024 | 49 | 0.060 |
Why?
|
| Family Planning Services | 1 | 2024 | 40 | 0.060 |
Why?
|
| Urinary Tract Infections | 2 | 2014 | 75 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 31 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 29 | 0.050 |
Why?
|
| Sex Workers | 1 | 2021 | 9 | 0.050 |
Why?
|
| Outpatients | 1 | 2021 | 103 | 0.050 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 430 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2020 | 21 | 0.040 |
Why?
|
| Medical Overuse | 1 | 2020 | 36 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 168 | 0.040 |
Why?
|
| Patient Participation | 1 | 2022 | 227 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 596 | 0.040 |
Why?
|
| Bone Diseases | 1 | 1999 | 58 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 1999 | 9 | 0.040 |
Why?
|
| Synovial Membrane | 1 | 1999 | 29 | 0.040 |
Why?
|
| HIV Seroprevalence | 1 | 2018 | 9 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 147 | 0.040 |
Why?
|
| Transgender Persons | 1 | 2021 | 115 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 657 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 164 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 681 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 279 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1170 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 1999 | 3500 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2016 | 130 | 0.030 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 24 | 0.030 |
Why?
|
| DNA, Fungal | 1 | 2016 | 58 | 0.030 |
Why?
|
| RNA, Ribosomal | 1 | 2016 | 67 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 125 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2016 | 89 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1082 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1994 | 25 | 0.030 |
Why?
|
| Ontario | 1 | 2014 | 51 | 0.030 |
Why?
|
| Ciprofloxacin | 1 | 2014 | 30 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1599 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1063 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 1994 | 140 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 872 | 0.030 |
Why?
|
| Bone Marrow | 1 | 1994 | 446 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 2510 | 0.030 |
Why?
|
| Prognosis | 2 | 2017 | 3825 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2012 | 75 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 147 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 1310 | 0.020 |
Why?
|
| Contrast Media | 1 | 1994 | 1085 | 0.020 |
Why?
|
| Gadolinium DTPA | 2 | 1999 | 256 | 0.020 |
Why?
|
| Bone Cysts | 1 | 1999 | 8 | 0.010 |
Why?
|
| Synovitis | 1 | 1999 | 14 | 0.010 |
Why?
|
| Finger Joint | 1 | 1999 | 14 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 810 | 0.010 |
Why?
|
| Laminectomy | 1 | 1994 | 28 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1994 | 152 | 0.010 |
Why?
|